[1] TIPTON CM, HOM JR, FUCILE CF, et al. Understanding B-cell activation and autoantibody repertoire selection in systemic lupus erythematosus: a B-cell immunomics approach[J]. Immunol Rev, 2018, 284(1): 120. doi: 10.1111/imr.12660
[2] STOHL W. Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)[J]. Expert Rev Clin Immunol, 2017, 13(6): 623. doi: 10.1080/1744666X.2017.1291343
[3] MURPHY G, ISENBERG DA. New therapies for systemic lupus erythematosus - past imperfect, future tense[J]. Nat Rev Rheumatol, 2019, 15(7): 403. doi: 10.1038/s41584-019-0235-5
[4] FANOURIAKIS A, KOSTOPOULOU M, ALUNNO A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(6): 736. doi: 10.1136/annrheumdis-2019-215089
[5] NAVARRA SV, GUZMÁN RM, GALLACHER AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2011, 377(9767): 721. doi: 10.1016/S0140-6736(10)61354-2
[6] FURIE R, PETRI M, ZAMANI O, et al. A phase Ⅲ, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2011, 63(12): 3918. doi: 10.1002/art.30613
[7] SCIASCIA S, RADIN M, YAZDANY J, et al. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review[J]. Autoimmun Rev, 2017, 16(3): 287. doi: 10.1016/j.autrev.2017.01.010
[8] FURIE R, ROVIN BH, HOUSSIAU F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis[J]. N Engl J Med, 2020, 383(12): 1117. doi: 10.1056/NEJMoa2001180
[9] ANJO C, MASCARÓ JR JM, ESPINOSA G, et al. Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting[J]. Scand J Rheumatol, 2019, 48(6): 469. doi: 10.1080/03009742.2019.1603324
[10] IACCARINO L, ANDREOLI L, BOCCI EB, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study[J]. J Autoimmun, 2018, 86: 1. doi: 10.1016/j.jaut.2017.09.004
[11] CAVAZZANA I, KUMAR R, POZZARI C, et al. Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus[J]. Lupus, 2019, 28(9): 1074. doi: 10.1177/0961203319860191
[12] WALLACE DJ, GINZLER EM, MERRILL JT. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus[J]. Arthritis Rheumatol, 2019, 71(7): 1125. doi: 10.1002/art.40861
[13] ZHANG FC, BAE SC, BASS D, et al. A pivotal phase Ⅲ, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea[J]. Ann Rheum Dis, 2018, 77(3): 355. doi: 10.1136/annrheumdis-2017-211631
[14] COLLINS CE, DALL'ERA M, KAN H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA[J]. Lupus Sci Med, 2016, 3(1): e000118. doi: 10.1136/lupus-2015-000118
[15] OON S, HUQ M, GODFREY T, et al. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus[J]. Semin Arthritis Rheum, 2018, 48(2): 221. doi: 10.1016/j.semarthrit.2018.01.001
[16] VON KEMPIS J, DUETSCH S, REUSCHLING N, et al. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland[J]. Swiss Med Wkly, 2019, 149: w20022.